BACKGROUND: The impact of postoperative adjuvant chemotherapy on the oncological outcomes for stage II colorectal cancer remains controversial. METHODS: The literature was searched for studies published between 1985 and 2010 in which patients with stage II colorectal cancer were randomly assigned to receive either surgery combined with postoperative adjuvant chemotherapy or surgery alone. End points included 5-year overall survival, 5-year disease-free survival, recurrence, and mortality. RESULTS: A significant improvement in 5-year overall survival was associated with surgery combined with postoperative adjuvant chemotherapy for stage II colon cancer (hazard ratio, 0.81; 95% confidence interval (CI), 0.71-0.91) and for stage II rectal cancer (hazard ratio, 0.72; 95% CI, 0.61-0.86). The 5-year disease-free survival also favored the group of surgery combined with postoperative adjuvant chemotherapy for stage II colon cancer (hazard ratio, 0.86; 95% CI, 0.75-0.98) and for stage II rectal cancer (hazard ratio, 0.34; 95% CI, 0.22-0.51). For stage II colon cancer, a significant reduction in risk of recurrence was found in favor of postoperative adjuvant chemotherapy (risk ratio, 0.82; 95% CI, 0.71-0.95). CONCLUSIONS: Postoperative adjuvant chemotherapy for stage II colorectal cancer appears to be associated with improved 5-year overall survival and 5-year disease-free survival, and reduction in risk of recurrence.
BACKGROUND: The impact of postoperative adjuvant chemotherapy on the oncological outcomes for stage II colorectal cancer remains controversial. METHODS: The literature was searched for studies published between 1985 and 2010 in which patients with stage II colorectal cancer were randomly assigned to receive either surgery combined with postoperative adjuvant chemotherapy or surgery alone. End points included 5-year overall survival, 5-year disease-free survival, recurrence, and mortality. RESULTS: A significant improvement in 5-year overall survival was associated with surgery combined with postoperative adjuvant chemotherapy for stage II colon cancer (hazard ratio, 0.81; 95% confidence interval (CI), 0.71-0.91) and for stage II rectal cancer (hazard ratio, 0.72; 95% CI, 0.61-0.86). The 5-year disease-free survival also favored the group of surgery combined with postoperative adjuvant chemotherapy for stage II colon cancer (hazard ratio, 0.86; 95% CI, 0.75-0.98) and for stage II rectal cancer (hazard ratio, 0.34; 95% CI, 0.22-0.51). For stage II colon cancer, a significant reduction in risk of recurrence was found in favor of postoperative adjuvant chemotherapy (risk ratio, 0.82; 95% CI, 0.71-0.95). CONCLUSIONS: Postoperative adjuvant chemotherapy for stage II colorectal cancer appears to be associated with improved 5-year overall survival and 5-year disease-free survival, and reduction in risk of recurrence.
Authors: Bengt Glimelius; Olav Dahl; Björn Cedermark; Anders Jakobsen; Søren M Bentzen; Hans Starkhammar; Henrik Grönberg; Ragnar Hultborn; Maria Albertsson; Lars Påhlman; Kjell-Magne Tveit Journal: Acta Oncol Date: 2005 Impact factor: 4.089
Authors: N Wolmark; H Rockette; D L Wickerham; B Fisher; C Redmond; E R Fisher; M Potvin; R J Davies; J Jones; A Robidoux Journal: J Clin Oncol Date: 1990-09 Impact factor: 44.544
Authors: I Balslev; M Pedersen; P S Teglbjaerg; F Hanberg-Soerensen; J Bone; N O Jacobsen; J Overgaard; A Sell; K Bertelsen; E Hage Journal: Cancer Date: 1986-07-01 Impact factor: 6.860
Authors: B Fisher; N Wolmark; H Rockette; C Redmond; M Deutsch; D L Wickerham; E R Fisher; R Caplan; J Jones; H Lerner Journal: J Natl Cancer Inst Date: 1988-03-02 Impact factor: 13.506
Authors: A Zaniboni; R Labianca; S Marsoni; V Torri; P Mosconi; R Grilli; G Apolone; S Cifani; A Tinazzi Journal: Cancer Date: 1998-06-01 Impact factor: 6.860
Authors: Anthony C Wong; Shannon Stock; Deborah Schrag; Katherine L Kahn; Talya Salz; Mary E Charlton; Selwyn O Rogers; Karyn A Goodman; Nancy L Keating Journal: J Oncol Pract Date: 2014-07-01 Impact factor: 3.840
Authors: Dimitrios Pectasides; Vasilios Karavasilis; George Papaxoinis; Georgia Gourgioti; Thomas Makatsoris; Georgia Raptou; Eleni Vrettou; Joseph Sgouros; Epaminontas Samantas; George Basdanis; Pavlos Papakostas; Dimitrios Bafaloukos; Vassiliki Kotoula; Haralambos P Kalofonos; Chrisoula D Scopa; George Pentheroudakis; George Fountzilas Journal: BMC Cancer Date: 2015-05-10 Impact factor: 4.430